Furiex Pharmaceuticals Confirms Takeda Will Present Additional Data from the EXAMINE Trial at the American College of Cardiology’s 63rd Annual Scientific Session

MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that its partner Takeda Pharmaceuticals Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s (ACC) 63rd Annual Scientific Session in Washington, DC. These sub-analyses specifically relate to the effects of alogliptin on rates of CV mortality and hospitalization for heart failure (HF).